GlobalData on MSN8d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
FiercePharma8d
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...
Zacks.com on MSN8d
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...
Managed Healthcare Executive8d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...
Cure Today9d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
pharmaphorum1d
Tecentriq is best value lung cancer immunotherapy, concludes ICER
This means Tecentriq still needs a discount of 31%-53% from the wholesale acquisition cost list price in order for it to be considered cost effective. For Opdivo, this is 57-68%, with Keytruda ...
Monthly Prescribing Reference8d
FDA Approves Tecentriq Hybreza, a Subcutaneously Administered PD-L1 Inhibitor
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
pharmaphorum6d
NICE recommends Roche's Tecentriq in ES-SCLC following price rethink
Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...
Business Wire9d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Morningstar1y
Genentech receives FDA approval for cancer treatment
The treatment, called Tecentriq Hybreza, can be injected under the skin through an injection over approximately seven minutes, compared with between 30 minutes and 60 minutes for a standard IV ...
Yahoo Finance8d
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab). The SC formulation was approved under the brand ...